ATE488581T1 - Faktor vii oder faktor viia polypeptidvarianten - Google Patents

Faktor vii oder faktor viia polypeptidvarianten

Info

Publication number
ATE488581T1
ATE488581T1 AT03717173T AT03717173T ATE488581T1 AT E488581 T1 ATE488581 T1 AT E488581T1 AT 03717173 T AT03717173 T AT 03717173T AT 03717173 T AT03717173 T AT 03717173T AT E488581 T1 ATE488581 T1 AT E488581T1
Authority
AT
Austria
Prior art keywords
factor
polypeptide variants
variants
viia polypeptide
vii
Prior art date
Application number
AT03717173T
Other languages
English (en)
Inventor
Jesper Haaning
Kim Andersen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of ATE488581T1 publication Critical patent/ATE488581T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03717173T 2002-04-30 2003-04-29 Faktor vii oder faktor viia polypeptidvarianten ATE488581T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37667902P 2002-04-30 2002-04-30
PCT/DK2003/000276 WO2003093465A1 (en) 2002-04-30 2003-04-29 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

Publications (1)

Publication Number Publication Date
ATE488581T1 true ATE488581T1 (de) 2010-12-15

Family

ID=29401388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03717173T ATE488581T1 (de) 2002-04-30 2003-04-29 Faktor vii oder faktor viia polypeptidvarianten

Country Status (22)

Country Link
US (6) US7700733B2 (de)
EP (1) EP1499719B1 (de)
JP (2) JP2005523723A (de)
KR (1) KR101121593B1 (de)
CN (2) CN101942019A (de)
AT (1) ATE488581T1 (de)
AU (2) AU2003221469A1 (de)
BR (1) BR0309576A (de)
CA (1) CA2483478A1 (de)
CY (1) CY1111626T1 (de)
DE (1) DE60334983D1 (de)
DK (1) DK1499719T3 (de)
ES (1) ES2355713T3 (de)
IL (1) IL164764A (de)
MX (1) MXPA04010781A (de)
NZ (1) NZ536340A (de)
PL (1) PL373728A1 (de)
PT (1) PT1499719E (de)
RU (1) RU2004134726A (de)
SI (1) SI1499719T1 (de)
WO (1) WO2003093465A1 (de)
ZA (1) ZA200409475B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
JP4472526B2 (ja) * 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
EP2085470B1 (de) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
EP2311437A1 (de) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
RU2396347C2 (ru) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
EP1831242B1 (de) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduktion des gehaltes an kontaminierenden proteinen in zusammensetzungen, die vitamin k-abhängige proteine von interesse umfassen
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
CN101268185B (zh) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2031968B1 (de) * 2006-04-21 2017-11-22 Wake Forest University Health Sciences Strukturell modifizierte azelluläre gewebe-engineering-gerüste und herstellungsverfahren
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
US8252302B2 (en) * 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
JP2011509978A (ja) 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2554161A1 (de) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
DK3165232T3 (da) 2012-12-24 2019-09-16 Coagulant Therapeutics Corp Faktor vii-polypeptider med kortvarig virkning
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
EP3833381B1 (de) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
EP0296413A2 (de) 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrides Protein C und Verfahren zur Herstellung
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
ATE300519T1 (de) 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
FI923347A0 (fi) 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
ATE180834T1 (de) 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
EP0785273A1 (de) 1990-11-26 1997-07-23 Genetics Institute, Inc. Gepaarte basische Aminosäuren konvertierendes Enzym und dafür kodierende DNA Sequenz
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
EP1479395A1 (de) 1991-02-28 2004-11-24 Novo Nordisk A/S Modifizierter Faktor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5504064A (en) 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
GB9122048D0 (en) * 1991-10-17 1991-11-27 Interox Chemicals Ltd Compositions and uses thereof
JPH0720127A (ja) 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
AU703110B2 (en) 1993-05-21 1999-03-18 Novo Nordisk A/S Modified factor VII
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
ATE321846T1 (de) 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE263778T1 (de) 1998-10-30 2004-04-15 Novozymes As Niedrigallergene proteinvarianten
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
JP4463988B2 (ja) 1998-11-06 2010-05-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子の生産方法
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
EP2226385B1 (de) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Varianten des menschlichen Koagulationsfaktors VII
RU2326126C2 (ru) 2000-09-13 2008-06-10 Ново Нордиск Хелт Кэр Аг Полипептид фактора vii свертывания крови, его получение и применение
AU2001291653A1 (en) 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
ES2432967T3 (es) 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
HUP0500060A3 (en) 2001-09-27 2010-01-28 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7024693B2 (en) * 2001-11-13 2006-04-04 Sun Microsystems, Inc. Filter-based attribute value access control
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
JP4472526B2 (ja) 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
EP2085470B1 (de) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
JP4915918B2 (ja) 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
US7185570B2 (en) 2005-01-18 2007-03-06 Chih-Ching Hsieh Spanner with enhancing structure for positioning electronic devices installed therein
US20060252669A1 (en) 2005-05-06 2006-11-09 Marija Heibel Fabric care composition comprising polymer encapsulated fabric or skin beneficiating ingredient

Also Published As

Publication number Publication date
US20060270000A1 (en) 2006-11-30
US7700733B2 (en) 2010-04-20
JP2005523723A (ja) 2005-08-11
EP1499719B1 (de) 2010-11-17
BR0309576A (pt) 2005-02-09
US20060276377A1 (en) 2006-12-07
DK1499719T3 (da) 2011-02-28
CN1665925A (zh) 2005-09-07
EP1499719A1 (de) 2005-01-26
MXPA04010781A (es) 2005-03-07
CN101942019A (zh) 2011-01-12
KR20040106424A (ko) 2004-12-17
PT1499719E (pt) 2011-02-09
IL164764A0 (en) 2005-12-18
RU2004134726A (ru) 2005-06-10
CY1111626T1 (el) 2015-10-07
US20060270001A1 (en) 2006-11-30
KR101121593B1 (ko) 2012-04-12
US9353365B2 (en) 2016-05-31
ES2355713T3 (es) 2011-03-30
US20100260741A1 (en) 2010-10-14
US20060111282A1 (en) 2006-05-25
AU2003221469A1 (en) 2003-11-17
PL373728A1 (en) 2005-09-05
DE60334983D1 (de) 2010-12-30
WO2003093465A1 (en) 2003-11-13
SI1499719T1 (sl) 2011-03-31
AU2008261165A1 (en) 2009-01-15
JP2010213706A (ja) 2010-09-30
US20060270002A1 (en) 2006-11-30
NZ536340A (en) 2006-09-29
CA2483478A1 (en) 2003-11-13
ZA200409475B (en) 2005-09-28
IL164764A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
DE60334983D1 (de) Faktor vii oder faktor viia polypeptidvarianten
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DK1257295T3 (da) Faktor VII eller VIIA-lignende molekyler
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
DE69809558D1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
ATE295829T1 (de) Verwendung von biologisch aktivem glas zum schneiden von biologisch aktivem glas
PL370536A1 (en) Compositions for treatment of common cold
DK2085470T3 (da) FVII- eller FVIIa-varianter
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
ATE389013T1 (de) Faktor x-analoge mit verbesserter fähigkeit zur aktivierung
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
DE60222669D1 (de) Asthma-assoziiertes gen
IN2009CN00831A (de)
FR2830865B1 (fr) Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
EP1490388A4 (de) Neue zusammensetzungen und verfahren bei krebs, der mit einer veränderten exprimierung von kcnj9 assoziiert ist
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
DE60129133D1 (de) Verwendung von Clarithromycin zur Herstellung eines Medikaments für die Behandlung von Arthrosis deformans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1499719

Country of ref document: EP